Dr. Reddy’s acquiring Mayne Pharma’s U.S. generic portfolio for $90 million

The portfolio includes 45 commercial-, four pipeline- and 40 approved non-marketed products, including generics focused on women’s health, part of the basket that fetched $111 million revenue for the Australian firm in June 2022.

from | The Hindu